Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors

ConditionsChronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)Waldenstrom Macroglobulinaemia Lymphoplasmacytic Lymphoma Marginal Zone B Cell Lymphoma Mantle Cell Lymphoma

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorCentre Hospitalier de la côte Basque

About this trial

This pilot prospective study aims to evaluate adherence to home blood pressure monitoring using connected blood pressure (BP) devices in patients with malignant B-cell hemopathies initiating covalent Bruton tyrosine kinase inhibitors (cBTKi). The objective is to determine whether digital BP monitoring improves early detection and management of BTKi-induced hypertension over 6 months.

Eligibility criteria

Qualifiers

Age ≥18 years

Diagnosis of lymphoid malignancy: chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, or mantle cell lymphoma

Initiation of oral BTK inhibitor therapy (ibrutinib, acalabrutinib, or zanubrutinib), in treatment-naive or relapsed patients

Affiliation with a social security system

Disqualifiers

Known cognitive impairment

No internet access

Individuals under guardianship, curatorship, or legal protection

Trial design

Treatments tested in this trial

Connected home blood pressure monitoring with daily IPA supervision.

Treatment groups

40 Participants

are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Centre Hospitalier de la côte Basque

Lead sponsor

Source ClinicalTrials.gov